# US 2015/0147389 A1 · Novel antioxidant formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147389 A1
- Document ID: US20150147389A1
- Status: Published application
- Kind: A1
- Application number: 14/550,859
- Filed: 2014-11-21
- Published: 2015-05-28
- Earliest claimed: 2013-11-22
- Inventors: Phillip E. Schoenwetter
- Web page: https://patentgrep.com/patent/US20150147389A1

## CPC

- A61K 36/296: Epimedium
- A61K 31/015: carbocyclic
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An antioxidant composition comprises one or more amino acids; a genistein alternative selected from the group consisting of genistein, aglycon genistine, hormone receptive modulators, phosphordiesterase (PDE) inhibitors of types 1, 2, 3 and 4, anti-neoplastic tyrosine kinase inhibitors, and combinations thereof; and an icariin alternative selected from the group consisting of icarosides 1 or 2, PDE-4 inhibitors, PDE-5 inhibitors, derivatives of the epimedium species including icarrocides I and II, and combinations thereof.

## Claims

### Claim 1

An antioxidant composition comprising:
one or more amino acids; a genistein alternative selected from the group consisting of genistein, aglycon genistine, hormone receptive modulators, phosphordiesterase (PDE) inhibitors of types 1, 2, 3 and 4, anti-neoplastic tyrosine kinase inhibitors, and combinations thereof; and an icariin alternative selected from the group consisting of icarosides 1 or 2, PDE-4 inhibitors, PDE-5 inhibitors, derivatives of the epimedium species including icarrocides I and II, and combinations thereof.

### Claim 2 (depends on 1)

The antioxidant composition of claim 1 wherein the amino acid is N-acetyl cysteine.

### Claim 3 (depends on 1)

The antioxidant composition of claim 1 wherein the genistein alternative is genistein or aglycon genistine.

### Claim 4 (depends on 1)

The antioxidant composition of claim 1 wherein the icariin alternative is icariin or icarosides 1 or 2.

### Claim 5 (depends on 1)

The antioxidant composition of claim 1 further comprising an ingredient selected from the group consisting of resveratrol, vitamin E, vitamin C, selenium, vitamin A, alpha-lipoic acid, lutein, inactive substances and combinations thereof.

### Claim 6 (depends on 5)

The antioxidant composition of claim 5 wherein the inactive substances are selected from the group consisting of microcrystalline cellulose, silicon dioxide, magnesium stearate, caramel and combinations thereof.

### Claim 7 (depends on 1)

The antioxidant composition of claim 1 wherein the antioxidant composition comprises, in one capsule, from about 25 mg to about 250 mg of the amino acid, from about 25 mg to about 500 mg of the genistein alternative, and from about 5 mg to about 100 mg of the icariin alternative.

### Claim 8 (depends on 5)

The antioxidant composition of claim 5, wherein the antioxidant composition comprises, in one capsule, from about 25 mg to about 250 mg of the amino acid, from about 25 mg to about 500 mg of the genistein alternative, and from about 5 mg to about 100 mg of the icariin alternative, from about 60 IU to about 600 IU of vitamin E, from about 50 mg to about 500 mg of the vitamin C, from about 25 micrograms to about 50 micrograms of the L-selenomethionine, from about 5 mg to about 100 mg of the alpha-lipoic acid, from about 500 IU to about 2500 IU of the vitamin A, from about 10 mg to about 100 mg of the resveratrol, and from about 1 mg to about 5 mg of the lutein.

### Claim 9 (depends on 5)

The antioxidant composition of claim 5, wherein the antioxidant composition comprises, in four capsules, from about 100 mg to about 500 mg of the amino acid, from about 50 mg to about 1000 mg of the genistein alternative, and from about 10 mg to about 200 mg of the icariin alternative, from about 120 IU to about 1000 IU of the vitamin E, from about 100 mg to about 1000 mg of the vitamin C, from about 50 micrograms to about 200 micrograms of the L-selenomethionine, from about 10 mg to about 250 mg of the alpha-lipoic acid, from about 500 IU to about 5000 IU of the vitamin A, from about 50 mg to about 500 mg of the resveratrol, and from about 5 mg to about 25 mg of the lutein.

### Claim 10 (depends on 8)

The antioxidant composition of claim 8, wherein the icariin is provided in form of horny goat weed extract, the vitamin E is d-alpha tocopherol succinate, the vitamin C is calcium ascorbate, the selenium is L-selenomethionine, the resveratrol is polygonium cuspidatum, and the vitamin A is beta-carotene.

### Claim 11 (depends on 5)

The antioxidant composition of claim 5 wherein each ingredient is dry compounded or mixed in powder or granular form.

### Claim 12

A method for a mammal to mitigate oxidative stress, the method comprising:
providing an antioxidant composition in a dietary supplement form; and
causing the mammal to intake the antioxidant composition such that the antioxidant composition reduces damage to the mammal's DNA caused by the oxidative stress,
wherein the antioxidant composition comprises one or more amino acids; a genistein alternative selected from the group consisting of genistein, aglycon genistine, hormone receptive modulators, phosphordiesterase (PDE) inhibitors of types 1, 2, 3 and 4, anti-neoplastic tyrosine kinase inhibitors, and combinations thereof; and an icariin alternative selected from the group consisting of icarosides 1 or 2, PDE-4 inhibitors, PDE-5 inhibitors, derivatives of the epimedium species including icarrocides I and II, and combinations thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antioxidant composition further comprises an ingredient selected from the group consisting of resveratrol, vitamin E, vitamin C, L-selenomethionine, vitamin A, alpha-lipoic acid, lutein, inactive substances and combinations thereof.

### Claim 14 (depends on 12)

The method of claim 12 wherein the antioxidant composition comprises, in a preferable daily dosage, from about 100 mg to about 500 mg of the amino acid, from about 50 mg to about 1000 mg of the genistein alternative, and from about 10 mg to about 200 mg of the icariin alternative.

### Claim 15 (depends on 14)

The method of claim 14 wherein the antioxidant composition further comprises, in a preferable daily dosage, from about 120 IU to about 1000 IU of the vitamin E, from about 100 mg to about 1000 mg of the vitamin C, from about 50 micrograms to about 200 micrograms of the L-selenomethionine, from about 10 mg to about 250 mg of the alpha-lipoic acid, from about 500 IU to about 5000 IU of the vitamin A, from about 50 mg to about 500 mg of the resveratrol, and from about 5 mg to about 25 mg of the lutein.

### Claim 16

A method of treating a mammal with one or more of the following conditions and ailments including osteoporosis, exposure to radiation, gonad hormone deficiency either natural or surgical caused, exposure to water or/and air pollution, exposure to outdoor environments, and exposure to natural or artificial light, the method comprising causing the mammal with the ailments or conditions to ingest or intake a composition comprising one or more amino acids; a genistein alternative selected from the group consisting of genistein, aglycon genistine, hormone receptive modulators, phosphordiesterase (PDE) inhibitors of types 1, 2, 3 and 4, anti-neoplastic tyrosine kinase inhibitors, and combinations thereof; and an icariin alternative selected from the group consisting of icarosides 1 or 2, PDE-4 inhibitors, PDE-5 inhibitors, derivatives of the epimedium species including icarrocides I and II, and combinations thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the composition further comprises an ingredient selected from the group consisting of resveratrol, vitamin E, vitamin C, L-selenomethionine, vitamin A, alpha-lipoic acid, lutein, inactive substances and combinations thereof.

### Claim 18 (depends on 16)

The method of claim 16, wherein the antioxidant composition comprises, in a preferable daily dosage, from about 100 mg to about 500 mg of the amino acid, from about 50 mg to about 1000 mg of the genistein alternative, and from about 10 mg to about 200 mg of the icariin alternative.

### Claim 19 (depends on 18)

The method of claim 18, wherein the antioxidant composition further comprises, in a preferable daily dosage, from about 120 IU to about 1000 IU of the vitamin E, from about 100 mg to about 1000 mg of the vitamin C, from about 50 micrograms to about 200 micrograms of the L-selenomethionine, from about 10 mg to about 250 mg of the alpha-lipoic acid, from about 500 IU to about 5000 IU of the vitamin A, from about 50 mg to about 500 mg of the resveratrol, and from about 5 mg to about 25 mg of the lutein.
